Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI AG 2022-03-01
Серии:Tomography
Предметы:
glioblastoma
histone deacetylase
epigenetic drug
radiation sensitizer
magnetic resonance spectroscopy
Online-ссылка:https://www.mdpi.com/2379-139X/8/2/57
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы